Tyvaso, a marketed PAH therapy from United Therapeutics, continued to show potential in another lung condition. Elsewhere, ...

In this video, Brian S. Kim, MD, discusses the management of patients with severe chronic spontaneous urticaria.

So, the current treatment options for chronic spontaneous urticaria include antihistamines, which have always been used at ...

Piper Sandler starts Regeneron at overweight with $875 price target, citing Dupixent growth and pipeline catalysts. Read more ...

Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of ...

Connect Biopharma has reported 52-week improvements across multiple endpoints in a phase 3 trial of its eczema drug candidate, fueling the biotech’s belief that its molecule is ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 8 Best Debt Free Stocks to Buy Right Now. On March 24, 2026, ...

The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients ...

GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.

Top-line results from the OBERON and TITANIA trials showed that tozorakimab reduced the annualised rate of moderate-to-severe ...

Sanofi and Regeneron announced that Japan’s Ministry of Health, Labour and Welfare has approved Dupixent (dupilumab) for ...